To assess how CD38 expression is modulated by ICB, we utilized pre-clinical of SCLC derived from genetically engineered mouse models (GEMM)with conditional loss of Rb1, Trp53 (RP), Rb1, Trp53 and p130 (RPP) or Rb1, Trp53, and MYCT58A (RPM) closely resembling the human disease (9, 10). This evidence concerns the gene TP53 and small cell lung carcinoma.